Total Funding
31
1
Total FundingDebt Financing raised
Growth Score
-4 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
921552
Meryx is a biotechnology company that develops orally bio-available cancer drugs targeting receptor tyrosine kinases.
- H. Shelton Earp: Co-Founder and Member
- Douglas Graham: Co-Founder and Member
About the Company
Meryx is a biotechnology company that develops orally bio-available cancer drugs targeting receptor tyrosine kinases. It focuses on developing drugs that inhibit tumor growth and initiate anti-tumor immunity in a range of cancers such as leukemia, lung cancer, and melanoma. It offers potent inhibitors of MerTK, such as MRX-2843, a clinical drug
candidate; and MRX-6313, a backup candidate that inhibit growth and initiate anti-tumor immunity in a range of hematologic and solid malignancies.
Meryx was founded in 2013 and is based in Chapel Hill, North Carolina.
